The Açaí Berry COVID-19 Anti-Inflammation Trial
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ana Andreazza, PhD
Department of Pharmacology & Toxicology; University of Toronto
Principal Investigator - Michael Farkouh, MD, MSc
Peter Munk Cardiac Centre; University Health Network; University of Toronto
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Instituto de Pesquisas Em Saude (ips)/ Universidade de Caxias Do Sul (ucs)
Caxias do Sul, Rio Grande do Sul, Brazil
- Instituto Prevent Senior (ips) - Hospital Sancta Maggiore
São Paulo, São Paulo, Brazil
- Heart Health Institute Research Inc
Toronto, Ontario, Canada
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Aug 2020
- Primary completion
- 15 Jun 2022
- Completion
- 31 Dec 2022
- Last update posted
- 31 May 2022
- Registered enrollment
- 480
- Registry id
- NCT04404218
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.